UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

Filed by the Registrant   ☒                             Filed by a Partyparty other than the Registrant   ☐

Check the appropriate box:

Global Blood Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box)all boxes that apply):

GLOBAL BLOOD THERAPEUTICS, INC.

181 Oyster Point Boulevard

South San Francisco, CA 94080

NOTICE OF ANNUAL MEETING

OF STOCKHOLDERS

TO BE HELD ON JUNE 17, 202014, 2022

Dear Stockholder:

You are cordially invited to attend the 20202022 Annual Meeting of Stockholders (the “Annual Meeting”) of Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), to be held on Wednesday,Tuesday, June 17, 202014, 2022, at 8:00 a.m. local time.(Pacific Time). Our Board of Directors has determined, in the interestsinterest of public health and safety in light of the ongoingCOVID-19 pandemic, that this year’s Annual Meeting will be held virtually via a live interactive audio webcast on the Internet. You will be able to vote and to ask questions of, and engage in dialogue with, members of our Board of Directors and senior management at www.virtualshareholdermeeting.com/GBT2020GBT2022 during the meeting. Our Board of Directors currently intends to hold future stockholder meetings in person or using a “hybrid”in-person and virtual format as soon as practicable once it is safe to do so.

The Annual Meeting will be held for the following purposes:

These items of business are more fully described in the proxy statement accompanying this notice.

TheOur Board of Directors has fixed the close of business on Wednesday,Friday, April 22, 2020,2022, as the record date for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting, or at any adjournments of the Annual Meeting.

Your vote is important. Whether or not you plan to attend the Annual Meeting, you are urged to vote as soon as possible as instructed in the Important Notice Regarding the Availability of Proxy Materials that you will receive in the mail. You may vote via the Internet or telephone or via mail, by requesting, at any time on or before Tuesday, May 31, 2022, a printed copy of the proxy card at any time on or before Wednesday, June 3, 2020.card. Voting promptly will help us avoid the additional expense of further solicitation to assure a quorum at the Annual Meeting. If you attend the Annual Meeting and file with the Secretary of the Company an instrument revoking your proxy or a duly executed proxy bearing a later date, your proxy will not be used.

By Order of the Board of Directors

Ted W. Love, M.D.

President and Chief Executive Officer

South San Francisco, California

April 28, 20202022

TABLE OF CONTENTS

Global Blood Therapeutics, Inc.  ï2022 Proxy Statementi

GLOBAL BLOOD THERAPEUTICS, INC.

181 Oyster Point Boulevard

South San Francisco, CA 94080

PROXY STATEMENT

FOR THE 20202022 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JUNE 17, 202014, 2022

INFORMATION CONCERNING SOLICITATION AND VOTING

General

This proxy statement (“Proxy Statement”) is furnished in connection with the solicitation of proxies for use prior to or at the 20202022 Annual Meeting of Stockholders (the “Annual Meeting”) of Global Blood Therapeutics, Inc. (the “Company,” “we,” “us” and “our”), a Delaware corporation, to be held virtually at 8:00 a.m., local time, (Pacific Time) on Wednesday,Tuesday, June 17, 2020,14, 2022, and at any adjournments or postponements thereof for the following purposes:

Our Board of Directors has determined, in the interestsinterest of public health and safety in light of the ongoingCOVID-19 pandemic, that this year’s Annual Meeting will be held virtually via a live interactive audio webcast on the Internet at www.virtualshareholdermeeting.com/GBT2020.GBT2022. You will be able to vote and to ask questions of, and engage in dialogue with, members of our Board of Directors and senior management during the meeting. Our Board of Directors currently intends to hold future stockholder meetings in person or using a “hybrid”in-person and virtual format as soon as practicable once it is safe to do so.

On or about April 28, 2020,2022, we will mail to all stockholders entitled to vote at the Annual Meeting a Notice of Internet Availability of Proxy Materials, or Notice, containing instructions on how to access this Proxy Statement and our Annual Report onForm 10-K for the fiscal year ended December 31, 2019,2021, or Annual Report.

Solicitation

This solicitation is made on behalf of theour Board of Directors. We will bear the costs of preparing, mailing, online processing and other costs of the proxy solicitation made by our Board of Directors. Certain of our officers and employees may solicit the submission of proxies authorizing the voting of shares in accordance with theour Board of Directors’ recommendations. In addition, we have engaged a proxy solicitor, Alliance Advisors, LLC, to assist us in the solicitation of proxies for aggregate fees of approximately $15,000, plus reasonable out-of-pocket expenses. Such solicitations may be made by email, telephone facsimile transmission or personal solicitation. No additional compensation will be paid to suchour officers, directors or regular employees for such services. We will reimburse banks, brokerage firms and other custodians, nominees and fiduciaries for reasonableout-of-pocket expenses incurred by them in sending proxy materials to stockholders.

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement1

Important Notice Regarding the Availability of Proxy Materials

In accordance with rules and regulations of the Securities and Exchange Commission, or the SEC, instead of mailing a printed copy of our proxy materials to each stockholder of record, we may furnish proxy materials via the Internet. Accordingly, all of our stockholders will receive a Notice, to be mailed on or about April 28, 2020.2022.

Proposal Two—Approval, on aNon-Binding, Advisory Basis, of the Compensation of our Named Executive Officers

Approval of this proposal requires the affirmative vote of a majority of the votes properly cast for and against this proposal. You may vote “FOR,” “AGAINST” or “ABSTAIN” from voting on this proposal. If you abstain from voting on this proposal, your shares will not be counted as “votes cast” with respect to this proposal, and the abstention will have no effect on this proposal. This proposal is not considered to be a routine item, so if you do not instruct your broker how to vote with respect to this proposal, your broker may not vote on this proposal, and those votes will be counted as broker“non-votes.” Brokernon-votes will have no effect on the outcome of this proposal.

Proposal Three—Approval of the Ratification of KPMG LLP as Independent Registered Public Accounting Firm

Approval of this proposal requires the affirmative vote of a majority of the votes properly cast for and against this proposal. You may vote “FOR,” “AGAINST” or “ABSTAIN” from voting on this proposal. If you abstain from voting on this proposal, your shares will not be counted as “votes cast” with respect to this proposal, and the abstention will have no effect on the proposal. This proposal is considered to be a discretionary item, and your broker will be able to vote on this proposal even if it does not receive instructions from you. Accordingly, we do not anticipate that there will be any brokernon-votes on this proposal; however, any brokernon-votes will not be counted as “votes cast” and will, therefore, have no effect on this proposal.

Voting Methods

We request that you vote your shares by proxy as instructed in the Notice by one of the following methods: over the Internet, by telephone or by mail. If you choose to vote by mail, your shares will be voted in accordance with your voting instructions if the proxy card is received prior to or at the Annual Meeting. If you sign and return your proxy card but do not give voting instructions, your shares will be voted FOR (i) the election of each of the three nominees as Class III directors; (ii) the approval, on anon-binding, advisory basis, of the compensation of our named executive officers; (iii) the ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2020;2022; and (iv) as the proxy holders deem advisable, in their discretion, on other matters that may properly come before the Annual Meeting.

Voting by Proxy Over the Internet or by Telephone

Stockholders whose shares are registered in their own names may vote by proxy by mail, over the Internet or by telephone. Instructions for voting by proxy over the Internet or by telephone are set forth on the Notice. The Internet and telephone voting facilities will close at 11:59 p.m. (Eastern Time) on June 16, 2020.13, 2022. The Notice will also provide instructions on how you can elect to receive future proxy materials electronically or in printed form by mail. If you choose to receive future proxy materials electronically, you will receive an email next year with instructions containing a link to the proxy materials and a link to the proxy voting site. Your election to receive proxy materials electronically or in printed form by mail will remain in effect until you terminate such election.

If your shares are held in street name, the voting instruction form sent to you by your broker, bank or other nominee should indicate whether the institution has a process for beneficial holders to provide voting instructions over the Internet or by telephone. A number of banks and brokerage firms participate in a program

Stockholder Proposals to be Presented at the Next Annual Meeting

Any stockholder who meets the requirements of the proxy rules under the Securities Exchange Act of 1934, as amended, or the Exchange Act, may submit proposals to the Board of Directors to be presented at the 20212023 Annual Meeting of Stockholders. Such proposals must comply with the requirements ofRule 14a-8 under the Exchange Act and be submitted in writing by notice delivered or mailed by first-class United States mail, postage prepaid, to our Secretary at our principal executive offices at the address set forth above no later than December 29, 2020,2022, to be considered for inclusion in the proxy materials to be disseminated by the Board of Directors for such annual meeting. If the date of the 20212023 Annual Meeting of Stockholders is moved by more than 30 days from the date contemplated at the time of the previous year’s proxy statement, then notice must be received within a reasonable time before we begin to print and send proxy materials. If that happens, we will publicly announce the deadline for submitting a proposal in a press release or in a document filed with the U.S. Securities and Exchange Commission, or SEC. A proposal submitted outside the requirements ofRule 14a-8 under the Exchange Act will be considered untimely if received after March 14, 2021.2023.

Our Amended and Restated Bylaws, or Bylaws, also provide for separate notice procedures to recommend a person for nomination as a director or to propose business to be considered by stockholders at a meeting. To be considered timely under these provisions, the stockholder’s notice must be received by our Secretary at our principal executive offices at the address set forth above no earlier than February 17, 2021,14, 2023, and no later than March 19, 2021.16, 2023. Our Bylaws also specify requirements as to the form and content of a stockholder’s notice.

The Board of Directors, a designated committee thereof or the chairmanchair of the meeting may refuse to acknowledge the introduction of any stockholder proposal if it is not made in compliance with the applicable notice provisions.

42022 Proxy Statementï  Global Blood Therapeutics, Inc.

PROPOSAL 1

ELECTION OF DIRECTORS

General

Our certificate of incorporation provides for a Board of Directors that is divided into three classes. The term for each class is three years, staggered over time. In 2020,2022, the term of the directors in Class III expires, and all three of our Class III directors—Mr. Willie L. Brown, Jr., Dr. Philip A. Pizzo Drs. Ted W. Love and Glenn F. Pierce and Ms. Wendy Yarno—Dawn A. Svoronos—will stand forre-election at the Annual Meeting.

Our Board of Directors is currently comprised of eightnine members. If the Class III director nominees who are standing forre-election are elected at the Annual Meeting, our Board of Directors will be as follows:

In the absence of instructions to the contrary, the persons named as proxy holders in the accompanying proxy intend to vote in favor of the election of the three Class III nominees designated below to serve until the 20232025 Annual Meeting of Stockholders and until their successors shall have been duly elected and qualified. Each nominee is currently a director. The Board of Directors expects that each nominee will be available to serve as a director, but if any such nominee should become unavailable or unwilling to stand for election, it is intended that the shares represented by the proxy will be voted for such substitute nominee as may be designated by the Board of Directors.

The biographies of our director nominees and each director whose term will continue after the Annual Meeting and their ages as of March 31, 20202022, are set forth below.

Class II:I: Director Nominees

The persons listed below are nominated for election to Class III of the Board of Directors to serve a three-year term ending at the 20232025 Annual Meeting of Stockholders and until their successors are elected and qualified.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR”

THE CLASS II

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE CLASS I DIRECTOR NOMINEES BELOW.

62022 Proxy Statementï  Global Blood Therapeutics, Inc.

Class II: Directors Currently Serving Until the 2023 Annual Meeting of Stockholders

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement7

Class III: Directors Currently Serving Until the 2024 Annual Meeting of Stockholders

82022 Proxy Statementï  Global Blood Therapeutics, Inc.

2022 Director Changes and Appointment of Director Emeritus

On March 24, 2022, Willie L. Brown, Jr.has resigned, effective immediately, from our Board of Directors and its Nominating and Corporate Governance Committee after serving as a director since January 2015. His resignation was not a result of any disagreement with the Company. On the same day, our Board of Directors appointed Mr. Brown as Director Emeritus, effective immediately, in which capacity he is serving as an advisor to the Company.

Mr. Brown served as a member of our Board of Directors sincefrom January 2015.2015 to March 2022. Since January 2004, Mr. Brown has served as an attorney at law representing clients before state and local governments. Prior to that, from January 1996 to January 2004, Mr. Brown served as the 41st mayor of San Francisco. Mr. Brown is a practicing attorney, community leader and well-respected public official who served over 31 years in the California State Assembly, spending more than 14 years as its Speaker, from 1980 to 1995. He currently serves as chairman and chief executive officer of The Willie L. Brown, Jr. Institute on Politics and Public Service, an independent,non-profit organization providing a forum fornon-partisan education, debate and discussion of public policy issues. Mr. Brown holds a degree in political science from San Francisco State University and a J.D. from University of California, Hastings College of the Law. He has received over 17 honorary degrees from prestigious institutions throughout his life.

On March 24, 2022, solely to provide for an equal apportionment of the members of the Board among the three classes of our classified Board following Mr. Brown’s qualificationsresignation, Dr. Thompson resigned from the Board as a Class I director, effective immediately, and was immediately reappointed by the remaining members of the Board as a Class II director, to serve onin such capacity until the next annual meeting of stockholders at which the term of the Class II directors expires or until her successor is duly elected and qualified, or her earlier death, resignation or removal.

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement9

Board Skills, Experience and Diversity

The below table provides information regarding our Board of Directors, include more than 50 years of political, businessincluding certain attributes possessed by our directors, which we andnon-profit experience.

Philip A. Pizzo, M.D.has served as a member of our Board of Directors since September 2015. Dr. Pizzo currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding directorbelieve are relevant to our business. The below table does not include all of the Stanford Distinguished Careers Institute. He previously served as Deanattributes of our directors, and the fact that a director may not have a particular attribute does not mean such director is unable to contribute to the decision-making process in that area.

Board composition overview

102022 Proxy Statementï  Global Blood Therapeutics, Inc.

As required by rules of the Stanford SchoolNASDAQ Stock Market that were approved by the Securities and Exchange Commission in August 2021, we are providing additional information about the gender and demographic diversity of Medicine from 2001 to 2012, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was thephysician-in-chief of Children’s Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School from 1996 to 2001. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific directorour directors in the Division of Clinical Sciences. Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs, has received numerous awards and honors, is a member of the National Academy of Medicine, and serves on several international boards. Dr. Pizzo holds a B.A. from Fordham University and an M.D. from the University of Rochester, School of Medicine. Dr. Pizzo’s qualifications to serve on our Board of Directors include his leadership in academic medicine, and his workformat required by NASDAQ rules. The information in the fields of pediatric medicine, science, educationmatrix below is based solely on information provided by our directors about their gender and healthcare.demographic self-identification.

Wendy Yarno has served as a member of our Board of Directors since December 2017. Ms. Yarno retired in September 2008 from Merck & Co, Inc. where she served in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer, before she retired. Prior to this position, Ms. Yarno served as General Manager for Merck’s Cardiovascular/Metabolic United States Business Unit and as Senior Vice President, Human Resources. From 2010 to 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company. Ms. Yarno currently serves on the boards of directors of the biopharmaceuticals companies Ideaya Biosciences, Inc., MyoKardia, Inc. and Inovio Pharmaceuticals, Inc. Ms. Yarno previously served as member of the board of directors of St. Jude Medical, Inc., Medivation, Inc., Alder Biopharmaceuticals, Inc., Aratana Biopharmaceuticals, Inc. and Durata

Class III: Directors Currently Serving Until the 2021 Annual Meeting of Stockholders

Scott W. Morrison has served as a member of our Board of Directors since January 2016. From 1996 to December 2015, Mr. Morrison was a partner at Ernst & Young LLP, a public accounting firm, and served as its U.S. Life Sciences Leader since 2002. He currently serves on the board of directors of Corvus Pharmaceuticals, Inc., a biopharmaceutical company and Ideaya Biosciences, Inc., a biotechnology company. Mr. Morrison served on the board and chaired the audit committee of Audentes, Inc. from December 2015 through its sale to Astellas Pharma Inc. in January 2020. Mr. Morrison has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center Board (now California Life Sciences Association), the California Life Sciences Foundation and the Biotechnology Institute. Mr. Morrison holds a B.S. in Accounting and Finance from the University of California, Berkeley and is a Certified Public Accountant (inactive). Mr. Morrison’s qualifications to serve on our Board of Directors include significant accounting expertise and knowledge of the life sciences industry through his35-year career in public accounting serving public and private companies in the life sciences sector, as well as his experience serving on the board of directors (and certain key standing committees) of other biotechnology companies since 2015.

Mark L. Perryhas served as a member of our Board of Directors since April 2015. From October 2012 to October 2013, Mr. Perry served as anentrepreneur-in-residence at Third Rock Ventures. Since August 2011, he has served on various boards of companies andnon-profit organizations. In October 2004, Mr. Perry joined Aerovance, Inc., a biopharmaceutical company, as a director, and he served as president and chief executive officer of Aerovance from February 2007 to October 2011. Prior to that, Mr. Perry served as the senior business adviser of Gilead Sciences, Inc., a biopharmaceutical company, from April 2004 to February 2007 and as an executive officer from May 1994 to April 2004, during which time he served in a variety of capacities, including general counsel, chief financial officer and executive vice president of operations. Earlier in his career, from 1981 to 1994, Mr. Perry served as an attorney at Cooley LLP, and was a partner of the firm from 1987 to 1994. Mr. Perry currently serves on the board of directors of Nvidia Corporation, a visual computing company, as the lead independent director, and MyoKardia, Inc., a biopharmaceutical company, as thenon-executive chairman of the board. Mr. Perry received a B.A. in history from the University of California, Berkeley and a J.D. from the University of California, Davis. Mr. Perry’s qualifications to serve on our Board of Directors include more than 30 years of experience serving in professional and management positions in the biotechnology industry, as well as his experience serving on the board of directors (and certain key standing committees) of other biopharmaceutical companies.

The following chart provides membership as of April 28, 2022, for each of the Board of Directors’ standing committees:

✔ - Committee member            C - Committee chair

Global Blood Therapeutics, Inc.  ï2022 Proxy StatementAudit Committee13

During 2021, Messrs. Morrison, Patrick and Perry and Ms. Svoronos currently serveserved on the Audit Committee, which is chaired by Mr. Morrison.and the Committee held four meetings. Our Board of Directors has determined that each of Mr.Messrs. Morrison, Patrick and Mr. Perry is an “Audit Committee financial expert,” as defined under the applicable rules of the SEC. The Audit Committee’s responsibilities include:

During 2019, Messrs. Morrison and Perry andIn April 2021, Ms. Svoronos served on the Audit Committee and the Committee held four meetings. Ms. Svoronos was appointedstepped down as a member of the Audit Committee on December 13, 2019. Deval L. Patrick, a former director who resigned in November 2019, also served on the Audit Committee from January 2019 to November 2019.

Compensation Committee

Messrs. Perry and Morrison and Ms. Yarno currently serve on the Compensation Committee, which is chaired by Ms. Yarno. The Compensation Committee’s responsibilities include:Committee.

During 2019, Mr.2021, Messrs. Brown Dr.and Patrick, and Drs. Pierce and Pizzo and Ms. Yarno served on the Nominating and Corporate Governance Committee, and the Committee held twothree meetings.

Research In March 2022, Mr. Brown resigned as a member and DevelopmentChair of the Nominating and Corporate Governance Committee (Advisory)

Ourin connection with his resignation from the Board of Directors formed a Research and Development Committee in March 2016. Drs. Pierceappointment as Director Emeritus, and Dr. Pizzo currently serve on the Research and Development Committee, which is chaired by Dr. Pierce. The Research and Development Committee’s responsibilities include providing advice and support related to our research and development programs, strategy and goals.

Commercial Committee (Advisory)

Our Board of Directors formed a Commercial Committee in December 2018. Ms. Yarno and Svoronos and Messrs. Morrison and Perry currently serve on the Commercial Committee, which is chaired by Ms. Svoronos. The Commercial Committee’s responsibilities include providing advice and support related to our potential and actual commercialization of any products, including our strategy and goals frompre-launch planning through any approval, launch and later phaseswas concurrently appointed as Chair of the product lifecycle.Nominating and Corporate Governance Committee.

Board Leadership

We do not currently have a ChairmanChair of the Board, but we have appointed Mr. Perry to serve as our lead independent director. We believe that the appointment of a lead independent director allows our Chief Executive Officer to focus on ourday-to-day business, while allowing the lead independent director to lead our Board of Directors in its fundamental role of providing advice to and independent oversight of management. Our Board of Directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business environment, as well as

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement15

the commitment required to serve as our lead independent director, particularly as our Board of Directors’ oversight responsibilities continue to grow.

While our Bylaws and corporate governance guidelines do not require that we appoint a separate ChairmanChair of the Board or lead independent director and Chief Executive Officer, our Board of Directors believes that having a Chief Executive Officer and a separate designated lead independent director is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance. Our separated lead independent director and Chief Executive Officer positions are augmented by the independence of seveneight of our eightnine directors, and our entirely independent Board committees that provide appropriate oversight in the areas described above. At executive sessions of independent directors, these directors speak candidly on any matter of interest, without the Chief Executive Officer or other executives present. The independent directors met four times in 20192021 without management present. We believe this structure provides consistent and effective oversight of our management and the Company.

In addition to those minimum qualifications, the Nominating and Corporate Governance Committee recommends that our Board of Directors select persons for nomination to help ensure that:

In addition to other standards the Nominating and Corporate Governance Committee may deem appropriate from time to time for the overall structure and compensation of the Board of Directors, the Nominating and Corporate Governance Committee may consider the following factors when recommending that our Board select persons for nomination:

experience, including gender diversity and representation of underrepresented groups, including as may be required by applicable law or the NASDAQ Stock Market Rules. Although we have no formal policy regarding board diversity, we and our Board of Directors strongly believe that corporate board diversity, including gender, racial and ethnic diversity, can provideprovides a more effective and dynamic Board of Directors that can better mitigate risk and enhance long-term performance for stockholders. Accordingly, the Nominating and Corporate Governance Committee considers whether nominees assist in achieving a mix of Board members that represents a diversity of background and experience.

The Nominating and Corporate Governance Committee adheres to the following process for identifying and evaluating nominees for the Board of Directors. First, it solicits recommendations for nominees fromnon-management directors, our Chief Executive Officer, other executive officers, third-party search firms or any other source it deems appropriate. The Nominating and Corporate Governance Committee then reviews and evaluates the qualifications of proposed nominees and conducts inquiries it deems appropriate; all proposed nominees are evaluated in the same manner, regardless of who initially recommended such nominee. In reviewing and evaluating proposed nominees, the Nominating and Corporate Governance Committee may consider, in addition to the minimum qualifications and other criteria for Board membership approved by our Board from time to time, all facts and circumstances that it deems appropriate or advisable, including, among other things, the skills of the proposed nominee, his or her depth and breadth of business experience or other background characteristics, his or her independence and the needs of the Board.

pursuant to the Director Compensation Policy are subject to full acceleration of vesting upon the consummation of a “Sale Event,” as defined in the 2015 Stock Option and Incentive Plan, or 2015 Plan. Ournon-employee directors could also be granted such additional stock options and RSUs in such amounts and on such dates as our Board of Directors recommended. All of the foregoing stock options would be granted with a per share exercise price equal to the fair market value of a share of our common stock on the date of grant and would be exercisable (to the extent vested) for up to one year following cessation of the director’s service on our Board of Directors, so long as the director was not removed for cause.

We have also agreed to reimburse all reasonableout-of-pocket expenses incurred bynon-employee directors in attending Board and committee meetings.

Stock Ownership Policy

In March 2020, we adopted a stock ownership policy for ournon-employee directors, which requires each director to acquire and hold a number of shares of our common stock equal in value to at least three times his or her applicable annual cash retainer for regular service on our Board of Directors, excluding any annual cash retainers paid for committee service, until such director’s service on the Board of Directors ceases. We only count directly and beneficially owned shares, including, with respect tonon-employee directors, 50% of shares underlying vested and unexercisedin-the-money stock options. Eachnon-employee director has until the later of April 1, 2025, or the Initial Determination Date, or the April 1^st1st in the year that is the fifth anniversary of his or her initial election to our Board of Directors, to attain the required ownership level. Once a director satisfies his or her stock ownership requirement, the director must continue to satisfy such stock ownership requirement as assessed on each April 1^st1st thereafter, or Determination Date. If a director fails to satisfy such stock ownership requirement as of any Determination Date (including the Initial Determination Date, as applicable)Date), then such director shall be required to come into compliance with his or her applicable stock ownership requirement within two years following the Determination Date on which he or she failed to satisfy such stock ownership requirement. As of April 1, 2022, 6 of our 8 non-employee directors met their stock ownership requirement, and the remaining non-employee directors have until the later of the Initial Determination Date or the April 1st in the year that is the fifth anniversary of his or her initial election to our Board of Directors to attain the required ownership level.

2019Environmental, Social and Governance Practices

Our mission is to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease. We view our environmental, social and governance, or ESG, practices as important pillars that should be aligned to the Company’s cultural values and guide us to achieve our mission and contribute to sustainable long-term performance, including recruiting and retaining the best talent. Published in April 2022, our inaugural ESG report focuses on four key areas in which we believe we will have impact and deliver long-term sustainable value for our business and society: improving access to affordable healthcare; investing in our employees and communities; increasing our environmental sustainability: and upholding our ethics and values. Responsibility for ESG strategy and management is led by functional experts throughout the Company and championed by our executive leadership team.

Environmental

We recognize that the sustainability of the Company is linked to our ability to understand and engage all our stakeholders in a consistent and meaningful manner. Starting with our Board of Directors and our executive leadership team, we are committed to long-term value driven by the pillars of governance, social responsibility, and integrity across all we do, including employee engagement, research and development, operations, commercialization and access to medicines for patients. Our efforts to help preserve the environment and reduce our impact on climate change include, among other things, our new headquarters that recently achieved LEED Silver certification; utilizing technology to reduce energy and water consumption; reducing, reusing and recycling our resources when practicable; partnering with third-party organizations for the ethical treatment of animals in research; and promoting employee commuting programs.

Social—Diversity, Equity & Inclusion

We have a values-driven culture that starts with our executive leadership team. Since our founding, we have recognized that having a more diverse, equitable and inclusive environment can help us to better deliver for patients through increased performance, better decision making, increased productivity and greater motivation. In addition, we believe that to foster innovation, increase access to care and reduce disparities, our workforce needs to be reflective of the patients and communities we serve and compensated in line with the value brought to patients, caregivers and communities.

We adopted the Workforce Development and Diversity & Inclusion, or WWDI, Principles created by the Biotechnology Innovation Organization, or BIO, to foster D&I among employees, customers and patients. We strive to make the Company a place where exceptionally talented candidates will be eager to work, collaborate and grow their careers—regardless of race, gender or sexual orientation.

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement19

Our team represents a broad range of cultural and professional backgrounds that enrich our company culture and drive our future growth and success:

among others, our Anti-Bribery and Anti-Corruption Policy, our Corporate Governance Guidelines, and our Insider Trading Policy. This periodic governance review also encompasses the structure and governance of our Board of Directors, voting standards for directors and other matters, and review of the Company’s defensive profile. The Nominating and Corporate Governance Committee is responsible for overseeing this governance review process, and each committee evaluates policies within its purview and recommends changes to our Board of Directors.

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement21

NON-EMPLOYEE DIRECTOR COMPENSATION

The Non-Employee Director Compensation Policy adopted by our Board of Directors is designed to provide a total compensation package, including cash, stock options and restricted stock units, or RSUs, that is competitive in the market to enable us to attract and retain, on a long-term basis, high-caliber non-employee directors. The Compensation Committee and our Board of Directors review non-employee director compensation and the Non-Employee Director Compensation Policy, including a competitive market assessment compared to peer companies, on an annual basis. In March 2021, the Compensation Committee reviewed our non-employee director compensation and Non-Employee Director Compensation Policy and recommended, and our Board of Directors agreed, to not make any changes to our non-employee director compensation as approved for 2020. The Non-Employee Director Compensation Policy for 2021 provided that all non-employee directors received cash retainers for service on our Board of Directors and committees of our Board of Directors as set forth below, prorated based on days of service during a calendar year.

In addition to the cash retainer amounts described above, the Non-Employee Director Compensation Policy also provides that each new non-employee director who is initially appointed or elected to our Board of Directors will receive a stock option and RSU grant. The Non-Employee Director Compensation Policy provides for an option to purchase shares of our common stock with an aggregate value of $415,000, subject to a maximum of 11,200 shares, and an RSU grant with an aggregate value of $415,000, subject to a maximum of 7,200 RSUs, in order to align their equity compensation with the 75th percentile of our peer companies but also to include a maximum share limit in the event of extraordinary market fluctuations. The initial stock option grant vests in equal monthly installments during the 36 months following the grant date, subject to the director’s continued service on our Board of Directors through each applicable vesting date. The initial RSU grant vests in equal annual installments during the three years following the grant date, subject to the director’s continued service on our Board of Directors through each applicable vesting date.

Thereafter, on the date of each annual meeting of stockholders, each continuing non-employee director is eligible to receive an annual stock option and RSU grant. The Non-Employee Director Compensation Policy provides for an option to purchase shares of our common stock with an aggregate value of $207,500, subject to a maximum of 5,600 shares, and an RSU grant with an aggregate value of $207,500, subject to a maximum of 3,600 RSUs, in order to align equity compensation with the 75th percentile of our peer companies but also to include a maximum share limit in the event of

222022 Proxy Statementï  Global Blood Therapeutics, Inc.

extraordinary market fluctuations. The annual stock option grant vests 1/12th on each month following the grant date for 11 months and the remaining 1/12th on the earlier of (i) the one-year anniversary of the grant date or (ii) our next annual meeting of stockholders, and such RSU grant vests on the earlier of (A) the one-year anniversary of the grant date or (B) our next annual meeting of stockholders, in each case subject to the director’s continued service on our Board of Directors through each applicable vesting date. If a non-employee director joins our Board of Directors on a date other than our annual meeting of stockholders, then such director will be granted, at our next annual meeting of stockholders, a pro-rata portion of the annual stock option and RSU grant based on the time between the non-employee director’s appointment and our next annual meeting of stockholders.

Under the Non-Employee Director Compensation Policy, this level of equity awards approximated the 75th percentile of the equity awards granted by our peer companies as our Board of Directors believed that such approach was necessary and appropriate in light of the highly competitive environment for qualified, experienced directors, met its desire to maintain continuity on our Board during our evolution to a commercial company, encouraged equity ownership by our non-employee directors and ensured a consistent equity award philosophy between our non-employee directors and executive officers. We believe this approach aligns our non-employee director compensation with our stockholder interests.

For awards of RSUs denominated in dollars, the number of shares to be subject to the award is determined by dividing the dollar value by the average closing market price on the NASDAQ Global Select Market of a share of our common stock over the trailing 20-trading day period ending on the trading day immediately preceding the grant date. For awards of stock options denominated by reference to a fair value calculated under FASB ASC Topic 718, the number of shares to be subject to such stock option is determined based on such fair value. In addition, all of the foregoing stock options are granted with a per share exercise price equal to the fair market value of a share of our common stock on the date of grant, and are exercisable (to the extent vested) for up to one year following cessation of the non-employee director’s service on our Board of Directors, so long as the director is not removed for cause.

All stock options and RSUs granted to our non-employee directors pursuant to the Non-Employee Director Compensation Policy are subject to full acceleration of vesting upon the consummation of a “Sale Event,” as defined in the 2015 Stock Option and Incentive Plan, as amended from time to time, or 2015 Plan. Our non-employee directors may also be granted such additional stock options and RSUs in such amounts and on such dates as our Board of Directors determines.

We have also agreed to reimburse all reasonable out-of-pocket expenses incurred by our non-employee directors in attending Board of Directors and committee meetings.

2021 Director Compensation Table

The table below sets forth information with respect to the compensation received by ournon-employee directors directors during the fiscal year ended December 31, 2019.2021. Dr. Love does not receive compensation for service on theour Board of Directors and the compensation paid to Dr. Love as an employee of the Company is set forth under the heading “Executive Compensation—20192021 Summary Compensation Table” below.

242022 Proxy Statementï  Global Blood Therapeutics, Inc.

PROPOSAL 2

NON-BINDING, ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

OFFICERS

The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or Dodd-Frank Act, added Section 14A toof the Securities Exchange Act of 1934, as amended, which requires that we provide our stockholders with the opportunity to vote to approve, on anon-binding, advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement, commonly known as a“Say-on-Pay” vote.

Stockholders may also abstain from voting. ThisSay-on-Pay vote is not intended to address any specific element of the compensation of our named executive officers, but rather the overall executive compensation of our named executive officers and our overall executive compensation program, philosophy, policies and practices as described in this Proxy Statement.

As described in this Proxy Statement, we believe the compensation of our named executive officers and our executive compensation program, philosophy, policies and practices are appropriate, and enable us to attract, motivate and retaintop-performing executive officers, including our named executive officers, while aligning the long-term interests of our executive officers with the long-term interests of our stockholders. Accordingly, we ask our stockholders to approve, on anon-binding, advisory basis, the following resolution at the Annual Meeting:

RESOLVED, that the compensation paid to the Company’s named executive officers as disclosed pursuant to Item 402 of RegulationS-K, including the Compensation Discussion and Analysis,, compensation tables and accompanying narrative discussion, is hereby APPROVED.

Required Vote

The approval of this advisorynon-binding proposal requires the affirmative vote of a majority of the voting power of the shares of our common stock present virtually or by proxy at the Annual Meeting and entitled to vote thereon. Abstentions and brokernon-votes will have no effect on this proposal.

ThisSay-on-Pay vote is advisory; therefore, it is not binding on the Company, our Board of Directors or ourthe Compensation Committee. However, our Board of Directors and ourthe Compensation Committee will consider the result of this year’s vote in reviewing and determining the compensation of our named executive officers in the future because we value the opinions of our stockholders.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE, ON ANON-BINDING, ADVISORY BASIS,

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement25

PROPOSAL 3

RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee has appointed KPMG LLP as our independent registered public accounting firm for 2020.2022. Representatives of KPMG LLP will attend the Annual Meeting and will have the opportunity to make a statement if they desire to do so. They will also be available to respond to appropriate questions.

Our organizational documents do not require that the stockholders ratify the selection of KPMG LLP as our independent registered public accounting firm, and stockholder ratification is not binding on the Company, the Board or the Audit Committee. We request such ratification, however, as a matter of good corporate practice. The ratification of the selection of KPMG LLP requires the affirmative vote of a majority of the votes cast on the proposal at the Annual Meeting. Our Board, including our Audit Committee, values the opinions of our stockholders and, to the extent there is any significant vote against the ratification of the selection of KPMG LLP as disclosed in this Proxy Statement, we will consider our stockholders’ concerns and evaluate what actions may be appropriate to address those concerns, although the Audit Committee, in its discretion, may still retain KPMG LLP.

The following table shows information about fees billed to the Company by KPMG LLP for the fiscal years ended December 31, 20192021 and 20182020:

Audit CommitteePre-Approval Policies

The Audit Committee is directly responsible for the appointment, retention and termination, and for determining the compensation, of our independent registered public accounting firm. The Audit Committee shallpre-approve all auditing services and the terms thereof andnon-audit services (other thannon-audit services prohibited under Section 10A(g) of the Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board), except thatpre-approval is not required for the provision ofnon-audit services if the “de minimus”minimis” provisions of Section 10A(i)(1)(B) of the Exchange Act are satisfied. The Audit Committee may delegate to the chairperson of the Audit Committee the authority to grantpre-approvals for audit andnon-audit services, provided such approvals are presented to the Audit Committee at its next scheduled meeting. All services provided by KPMG LLP during fiscal years 20192021 and 20182020 werepre-approved by the Audit Committee in accordance with thepre-approval policy described above.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR”

OF THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC

ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2020.262022 Proxy Statementï  Global Blood Therapeutics, Inc.

AUDIT COMMITTEE REPORT

The following Audit Committee Report is not considered proxy solicitation material and is not deemed filed with the Securities and Exchange Commission. Notwithstanding anything to the contrary set forth in any of our filings made under the Securities Act of 1933 or the Exchange Act that might incorporate our filings under those statutes, the Audit Committee Report shall not be incorporated by reference into any of our prior filings or into any of our future filings under those statutes.

The Audit Committee of the Board of Directors, or Audit Committee, has furnished this report concerning the independent audit of the Company’s financial statements. Each member of the Audit Committee meets the enhanced independence standards established by the Sarbanes-Oxley Act of 2002 and rulemaking of the Securities and Exchange Commission, or SEC, and the NASDAQ Stock Market regulations. A copy of the Audit Committee Charter is available on the Company’s website at http://www.gbt.com.

The Audit Committee’s responsibilities include assisting the Board of Directors regarding the oversight of the integrity of the Company’s financial statements, the Company’s compliance with legal and regulatory requirements, the independent registered public accounting firm’s qualifications and independence, and the performance of the independent registered public accounting firm.

In fulfilling its oversight responsibilities, the Audit Committee reviewed and discussed the Company’s financial statements for the fiscal year ended December 31, 2019,2021, with the Company’s management and KPMG LLP. In addition, the Audit Committee has discussed with management, and with KPMG LLP, with and without management present, their evaluation of the Company’s internal controlscontrol over financial reporting and overall quality of the Company’s financial reporting. The Audit Committee also discussed with KPMG LLP the matters required to be discussed by the Public Company Accounting Oversight Board and the SEC. The Audit Committee also received the written disclosures and the letter from KPMG LLP required by the Public Company Accounting Oversight Board Rule 3526 and the Audit Committee discussed the independence of KPMG LLP with that firm.

Based on the Audit Committee’s review and discussions noted above, the Audit Committee recommended to the Board of Directors, and the Board of Directors approved, that the audited financial statements be included in the Company’s Annual Report for the fiscal year ended December 31, 2019.2021.

The Audit Committee and the Board of Directors have recommended the selection of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020.2022.

AUDIT COMMITTEE

SCOTT W. MORRISON, CHAIRMANCHAIR

DEVAL L. PATRICK

MARK L. PERRY

DAWN SVORONOS

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement27

EXECUTIVE OFFICERS

The table below sets forth certain information regarding our executive officers as of March 31, 2020.2022.

Executive Officers

The biographies of our executive officers, other than Dr. Love, whose biography is set forth above, appear below.

Jeffrey Farrow has served as our Chief Financial Officer since April 2016. Mr. Farrow previously served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 where he was part of the team responsible for the successful regulatory approval and commercial launch of RAVICTI^® for the treatment of urea cycle disorders. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).

Brian Cathers, Ph.D. has served as our Chief Scientific Officer since February 2019. Dr. Cathers previously served as executive director and head of drug discovery at Celgene Corporation, or Celgene, from November 2015 to February 2019, and as senior director of biochemistry and structural biology at Celgene from October 2013 to November 2015. At Celegene, Dr. Cathers’ teams produced eight new development candidates and advanced five investigational drugs into clinical testing. Prior to joining Celgene, Dr. Cathers served as senior group leader and director at NewBiotics, Inc. from August 2000 to February 2004, where he oversaw enzymology and biophysical chemistry research, and was part of small team that developed a colorectal cancer drug from basic research to clinical testing. Prior to joining NewBiotics, he served as an enzymologist at Axys Pharmaceuticals. Dr. Cathers holds a B.S. in chemistry from Emporia State University and an M.S. and Ph.D. in medicinal chemistry from the University of Kansas.

Jung E. Choi has served as our Chief Business and Strategy Officer since April 2015. From April 2014 to March 2015, Ms. Choi served as senior vice president, corporate development for InterMune, Inc., a biotechnology company (acquired by Roche Holding AG in 2014), and served as an adviser on strategy and business development to InterMune from March 2013 to April 2014. Prior to joining InterMune, from February 2011 to March 2013, Ms. Choi led corporate and business development for Chimerix, Inc., a biopharmaceutical company, as a consultant and senior vice president, corporate development. Prior to that, from August 2001 to August 2010, Ms. Choi held various management positions at Gilead Sciences, Inc., a biopharmaceutical company, including leadership of business development, licensing, and mergers and acquisition activities. During

Mr. Johnson holds a B.A. in business marketing from the University of Puget Sound and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.

Carrie Krehlik has served as our Chief Human Resources Officer since August 2021. Prior to the Company, she served as senior vice president and chief human resources officer for Adicet Bio from November 2017 to May 2021, where she established the people strategy for the company as it initiated its first-in-human phase 1 trial of the company’s lead allogeneic CAR gamma-delta T cell therapy. Before that, Ms. Krehlik served as a senior consultant at Blue Beyond Consulting, LLC from July 2016 until November 2017, and was vice president, human resources at ZS Pharma (acquired by AstraZeneca) from July 2015 to June 2016. Prior to that, Ms. Krehlik was vice president of human resources of Hyperion Therapeutics, LLC (acquired by Horizon Pharma) from April 2015 until June 2015. From December 2012 until March 2015, she served as vice president, human resources at InterMune, Inc. (acquired by Roche Holding AG) where she was responsible for designing and implementing the culture and talent strategies at a time of rapid organizational expansion in preparation for the U.S. commercial launch of Esbriet^®. Previously, she held global management positions at Ericsson’s Internet Protocol and Broadband Business, Applied Biosystems and SAP. Ms. Krehlik received a B.S. in business administration from Miami University of Ohio, and an M.B.A. in international studies from San Francisco State University.

Kim Smith-Whitley, M.D., has served as our Executive Vice President and Head of Research and Development since May 2021. Most recently, she was the Clinical Director of Hematology and Director of the Comprehensive Sickle Cell Center at Children’s Hospital of Philadelphia (CHOP) from 1995, where she continues to see patients on a part-time basis. Dr. Smith-Whitley’s clinical work has centered on program development and clinical initiatives to support evidence-based clinical care. Her research has focused on sickle cell disease, specifically pulmonary complications, transfusion-related complications and health care utilization. She has served as principal investigator for several federally- and industry-funded clinical research studies including several clinical trials related to pain prevention and curative therapies. She is a former chief medical officer of the Sickle Cell Disease Association of America (SCDAA), where she has continued to serve as a member of the board of directors since September 2016. She has received numerous awards recognizing her expertise in teaching, advocacy and clinical care including the Master Clinician Awards at both CHOP and the University of Pennsylvania’s Perelman School of Medicine, where she has been a Professor of Pediatrics since 1996. Dr. Smith-Whitley received her M.D. from George Washington University and completed her postgraduate training at the Children’s National Medical Center and CHOP.

Tricia Suvari, Esq., has served as our Chief Legal Officer since October 2016. From 2000 until 2009, Ms. Suvari served in several senior roles at CV Therapeutics, Inc., a biopharmaceutical company (acquired by Gilead Sciences, Inc. in 2009), ultimately as senior vice president, general counsel and chief compliance officer. Prior to CV Therapeutics, from 1991 until 2000, she served as corporate counsel at Genentech, Inc., in increasingly senior roles. From February 2012 until July 2016, Ms. Suvari served as a vice president and general counsel at thenon-profit Peninsula Open Space Trust, and from early 2011 to February 2012 she served as an independent consultant to biopharmaceutical companies. Ms. Suvari earned her Bachelor of Sciences degree in Geology and Geophysics from Yale University and her J.D. degree from Harvard Law School.

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement29

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

This Compensation Discussion and Analysis, or CD&A, describes our executive compensation program and the 20192021 compensation for: (i) each individual who served as our principal executive officer during 2019;2021; (ii) each individual who served as our principal financial officer during 20192021 and (iii) our three most highly compensated executive officers during 20192021 other than the individuals set forth above in clauses (i) and (ii), all of whom we refer to collectively as our named executive officers, or NEOs. This CD&A should be read with the compensation tables and relatedaccompanying narrative disclosures for our NEOs.

Our NEOs for 20192021 were as follows:

Management Changes in 2019 and 2020

We hired Dr. Cathers in February 2019.

On September 17, 2019, our Board of Directors appointed Dr. Lehrer-Graiwer as our Chief Medical Officer, effective October 1, 2019. Prior to his appointment as our Chief Medical Officer, Dr. Lehrer Graiwer served as our SeniorExecutive Vice President, ClinicalHead of Research and Development. In February 2020, Dr. Lehrer-Graiwer resigned from his employment with our company, effective April 17, 2020.

confirmatory study we initiatedIn January 2021, the European Medicines Agency, or EMA, accepted for review our Marketing Authorization Application, or MAA, seeking full marketing authorization of Oxbryta, and, in December 2019 thatFebruary 2022, the European Commission, or EC, approved our MAA for Oxbryta for the treatment of hemolytic anemia (which is using transcranial Doppler, or TCD, flow velocitylow hemoglobin due to seekred blood cell destruction) due to demonstrate a decreaseSCD in stroke risk in children two to 15adult and pediatric patients 12 years of age)age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). We also expectSuch authorization includes all Member States of the European Union, as well as the additional Member States of the European Economic Area (Iceland, Liechtenstein and Norway). In addition, we have submitted an application to conduct additional clinical studiesthe Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom for a Great Britain Marketing Authorisation using the EC Decision Reliance Procedure.

Under the exclusive agreement with our distribution partner, Biopharma-Middle East and Africa, or Biopharma-MEA, we have continued to advance efforts to expand access to Oxbryta in the six countries that make up the GCC region (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, or UAE). In the GCC, the U.S. approval of Oxbryta includingcan be referenced to seekallow access to expand the potential approved product label into younger pediatric populations.medicine while health authorities conduct their reviews. In the third quarter of 2021, we were granted marketing authorization for Oxbryta by the Ministry of Health and Prevention (MOHAP) in the UAE for the treatment of SCD in adults and children 12 years of age and older, making the UAE the first country outside of the U.S. to grant regulatory approval of Oxbryta.

BeyondWe have ongoing and planned clinical trials in multiple countries to further evaluate the safety and efficacy of Oxbryta, and we are also engaged in other research and development activities. For example, we are advancing our SCDactivities beyond Oxbryta. Our product pipeline withincludes inclacumab, ap-selectinP-selectin inhibitor, which is a clinically validated target in developmentSCD, known to address painreduce the incidence of vaso-occlusive crises, associated with the disease.or VOCs, and our next generation hemoglobin polymerization inhibitor, GBT021601, or GBT601. In addition, our drug discovery team is working on new targets to develop the next generation of treatments for SCD.

As part of thoseour efforts to expand our pipeline, we have entered into in-license and collaboration agreements and regularly evaluate opportunities toin-license, acquire or invest in new business, technology or assets or engage in related discussions with other business entities. In December 2019,For example, in March 2021, we entered into a license and collaboration agreement or the Syros Collaboration, with Syros Pharmaceuticals, Inc.Sanofi S.A., or Syros,Sanofi, to discover, developexclusively in-license worldwide rights to two early-stage research programs in SCD: one that pursues a novel anti-sickling mechanism and commercialize novel therapiesanother that leverages a new approach to reduce inflammation and oxidative stress.

Overall, our business model is aligned with our social purpose, which is centered on highlighting the disparities and inequalities of people living with SCD. This includes helping to address these issues through education, support of and engagement with the SCD community, as well as charitable giving, such as through The GBT Foundation we established in 2021. We believe that fostering a values-driven culture, developing and supporting our people, and creating a more diverse, equitable and inclusive environment for our employees can help us to better deliver for SCD and beta thalassemia.patients.

We had 457 full-time employees globally as of December 31, 2021.

Corporate Performance Highlights

Our executive compensation program seeks to incentivize and reward strong corporate performance. Highlights of our 20192021 corporate performance are set forth below.

Global Blood Therapeutics, Inc.  ï2022 Proxy Statement31